Research Article
Pharmacological Mechanisms of Tinglizi against Chronic Heart Failure Determined by Network Pharmacology and Molecular Docking
Table 3
KEGG pathway enrichment results.
| | Pathway | Name | Number of targets | p.adjust |
| | hsa05418 | Fluid shear stress and atherosclerosis | 12 | 1.00E − 12 | | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 10 | 3.27E − 11 | | hsa04066 | HIF-1 signaling pathway | 9 | 2.35E − 09 | | hsa05417 | Lipid and atherosclerosis | 10 | 3.56E − 08 | | hsa05212 | Pancreatic cancer | 7 | 1.31E − 07 | | hsa04926 | Relaxin signaling pathway | 8 | 1.70E − 07 | | hsa01522 | Endocrine resistance | 7 | 5.65E − 07 | | hsa05142 | Chagas disease | 7 | 6.55E − 07 | | hsa05161 | Hepatitis B | 8 | 6.83E − 07 | | hsa05152 | Tuberculosis | 8 | 1.40E − 06 | | hsa05219 | Bladder cancer | 5 | 3.11E − 06 | | hsa04657 | IL-17 signaling pathway | 6 | 7.49E − 06 | | hsa05146 | Amoebiasis | 6 | 1.12E − 05 | | hsa05145 | Toxoplasmosis | 6 | 1.81E − 05 | | hsa04071 | Sphingolipid signaling pathway | 6 | 2.42E − 05 | | hsa05415 | Diabetic cardiomyopathy | 7 | 3.61E − 05 | | hsa05162 | Measles | 6 | 5.23E − 05 | | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 5 | 5.23E − 05 | | hsa05210 | Colorectal cancer | 5 | 7.54E − 05 | | hsa04932 | Nonalcoholic fatty liver disease | 6 | 8.41E − 05 | | hsa05222 | Small cell lung cancer | 5 | 9.51E − 05 | | hsa05323 | Rheumatoid arthritis | 5 | 9.57E − 05 | | hsa05215 | Prostate cancer | 5 | 0.000112447 | | hsa05144 | Malaria | 4 | 0.000150485 | | hsa04659 | Th17 cell differentiation | 5 | 0.000167799 | | hsa04931 | Insulin resistance | 5 | 0.000167799 | | hsa04668 | TNF signaling pathway | 5 | 0.000192705 | | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 6 | 0.000215762 | | hsa04010 | MAPK signaling pathway | 7 | 0.0002249 | | hsa04722 | Neurotrophin signaling pathway | 5 | 0.000232382 | | hsa05169 | Epstein-Barr virus infection | 6 | 0.000244682 | | hsa05205 | Proteoglycans in cancer | 6 | 0.000257499 | | hsa05321 | Inflammatory bowel disease | 4 | 0.000310948 | | hsa05166 | Human T-cell leukemia virus 1 infection | 6 | 0.000377637 | | hsa04210 | Apoptosis | 5 | 0.000377637 | | hsa05163 | Human cytomegalovirus infection | 6 | 0.000382944 | | hsa04915 | Estrogen signaling pathway | 5 | 0.000382944 | | hsa01524 | Platinum drug resistance | 4 | 0.000426283 | | hsa05133 | Pertussis | 4 | 0.000474104 | | hsa05166 | Human T-cell leukemia virus 1 infection | 6 | 0.000377637 |
|
|
